William Blair Has Pessimistic Outlook of CNTX Q3 Earnings

Key Points

• William Blair has revised its Q3 2025 earnings estimate for Context Therapeutics to ($0.09) per share, down from a previous estimate of ($0.07).
• Despite a pessimistic outlook, William Blair maintains an "Outperform" rating on the stock, with other firms also rating it as "Buy" with a consensus price target of $5.25.
• Insider trading activity includes significant purchases by the CFO and CEO, indicating confidence as they increase their positions in the company.

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Research analysts at William Blair decreased their Q3 2025 earnings per share (EPS) estimates for Context Therapeutics in a note issued to investors on Thursday, August 7th. William Blair analyst M. Phipps now expects that the company will earn ($0.09) per share for the quarter, down from their prior estimate of ($0.07). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics' Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.45) EPS and FY2028 earnings at ($0.62) EPS.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03).

Several other research firms have also recently issued reports on CNTX. D. Boral Capital reiterated a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Thursday. Piper Sandler restated an "overweight" rating and set a $4.00 target price (down previously from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. Finally, HC Wainwright cut their price objective on Context Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $5.25.

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX opened at $0.72 on Monday. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.75. The firm has a market cap of $64.57 million, a PE ratio of -2.00 and a beta of 1.89. The business has a fifty day moving average of $0.69 and a 200-day moving average of $0.75.

Insiders Place Their Bets

In related news, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of Context Therapeutics stock in a transaction dated Friday, June 6th. The shares were bought at an average cost of $0.64 per share, with a total value of $25,606.40. Following the acquisition, the chief financial officer owned 80,010 shares in the company, valued at $51,206.40. This trade represents a 100.03% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Martin A. Lehr bought 100,000 shares of Context Therapeutics stock in a transaction dated Monday, June 9th. The shares were bought at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the completion of the acquisition, the chief executive officer owned 920,190 shares in the company, valued at $644,133. This represents a 12.19% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 160,010 shares of company stock valued at $107,206. Corporate insiders own 3.04% of the company's stock.

Hedge Funds Weigh In On Context Therapeutics

Large investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of Context Therapeutics during the fourth quarter worth about $29,000. Citadel Advisors LLC acquired a new stake in Context Therapeutics in the fourth quarter valued at approximately $31,000. Shay Capital LLC acquired a new stake in Context Therapeutics in the fourth quarter valued at approximately $52,000. Walleye Capital LLC grew its stake in Context Therapeutics by 51.7% in the fourth quarter. Walleye Capital LLC now owns 166,306 shares of the company's stock valued at $175,000 after acquiring an additional 56,651 shares during the period. Finally, Millennium Management LLC boosted its position in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company's stock valued at $188,000 after buying an additional 34,835 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.